Ultragenyx Misses On Revenue, But Gene Therapy Approvals, $350 Million In Voucher Proceeds And Deep Cuts Push It Toward Profitability

Ultragenyx Pharmaceutical (NASDAQ: RARE) posted a third-quarter loss of $1.16 per share, a hair worse than the $1.15 consensus, for a 0.9% miss. Revenue of $173.0 million fell 6.1% short of the $184.25 million estimate. Year over year, the picture looks better: earnings improved 35.9% as the net loss narrowed to $118 million from $180 million, and revenue grew 8.2%. The miss itself matters less than what changed around it. Ultragenyx has become a different company. It won FDA approval for its first two gene therapies, GENGLYCOS and FAYUVI. It lost its largest pipeline value driver when GTX-102 failed in Angelman syndrome. Management responded with a second, deeper restructuring aimed squarely at 2027 GAAP profitability. The question for investors has shifted from pipeline optionality to commercial execution and cost discipline.

The quality of the improvement deserves scrutiny. The narrower loss came mainly from spending, not sales. R&D fell to $154 million from $216 million, while SG&A rose to $97 million from $87 million. The revenue shortfall traces largely to CRYSVITA, which slipped to $109 million from $112 million. Latin America and Türkiye product sales dropped to $41 million from $47 million, which management attributed to expected ordering patterns. The rest of the base business was healthier:

• DOJOLVI rose to $30 million from $24 million.
• EVKEEZA climbed to $24 million from $17 million.
• MEPSEVII reached $10 million from $7 million.

Non-cash interest on royalty-sale liabilities increased to $20 million from $14 million, and a $9 million tax benefit flattered the bottom line. The reaffirmed $730-$760 million revenue range, which excludes the new launches, still requires $207-$237 million in the fourth quarter after $523 million through nine months. That is a demanding step-up that hinges on CRYSVITA ordering timing.

The call preserved a credible growth story in the base business while confirming a much thinner pipeline.

• **Base business:** EVKEEZA is up roughly 50% year to date with more than 500 ex-U.S. patients. DOJOLVI reimbursed North American patients reached about 700, versus roughly 675 earlier in the year, with Japan exceeding expectations and a new UK authorization. CRYSVITA patients in Latin America topped 1,050, up from about 1,000 last quarter.
• **Launches:** 35 qualified treatment centers are active, with more than 40 targeted by year-end. Management cited meaningful enrollment forms and urgent demand for FAYUVI, and early payer policies are in line with the label.
• **Tone:** Management sounded more sober. Earlier in the year it had expressed high confidence in both GTX-102 endpoints and floated a potential voucher from that program as upside. ASPIRE instead failed across endpoints, which the company blamed on control-group variability.

The forward-looking ledger has moved sharply in both directions. On the positive side, Ultragenyx agreed to sell the two priority review vouchers for $413 million combined, with roughly $350 million in expected net proceeds. Prior calls had modeled just over $100 million apiece. Those proceeds matter because cash fell to $401 million from $737 million at year-end, and the balance sheet shows a $376 million stockholders' deficit. Management now targets 2027 R&D below $350 million, more than 50% below 2025 and deeper than the prior 38% reduction. It also said no further fundraising is needed to reach profitability, and that 2027 profitability does not depend on voucher income.

Bears have legitimate ammunition:

• UX701 for Wilson disease was terminated.
• Headcount is falling about 20%, on top of February's 10% cut, with roughly $25 million in fourth-quarter restructuring charges.
• 2027 SG&A is guided below $375 million, potentially up to 7% above 2025.
• The late-stage pipeline is down to DTX301, with data due in the first half of 2027, and setrusumab, whose regulatory path remains undefined.
• GENGLYCOS carries accelerated-approval confirmatory obligations, and FAYUVI faces competition from Denali's enzyme replacement therapy and a lentiviral gene therapy.
• CRYSVITA's composition-of-matter protection runs to roughly 2032.

The market has already absorbed much of this. Shares closed at $16.30 on November 2, ahead of the report. That is 42.8% below the $28.48 opening price after the August report and 28.9% below the 200-day moving average of $22.91. The stock peaked at $28.50 on August 20, then collapsed to a 52-week low of $12.73 on September 16, and has since recovered about 28% off that low. Investor sentiment improved meaningfully, from -0.29 at the prior report to roughly neutral at +0.04. That suggests expectations have reset rather than turned enthusiastic. The Earnings Whispers trend signals are mixed: momentum is positive, while the price and AVWAP trends remain negative, consistent with a stock bouncing within a damaged longer-term trend.

The bottom line is that the modest headline miss is the least important part of this report. Ultragenyx has traded its biggest pipeline bet for a leaner, commercially focused model, funded by better-than-modeled voucher proceeds and aggressive cost cuts. The case now rests on two near-term tests: delivering a strong fourth-quarter CRYSVITA order and ramping two gene therapy launches. Investors should hold management to its 2027 profitability target, which it has staked without the cushion of a deep pipeline.

Read our earnings preview for Ultragenyx Pharmaceutical Inc.: https://www.earningswhispers.com/article/RARE/21986

This earnings review was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.